Dr. Shulman on Chemotherapy in Adjuvant Breast Cancer

Partner | Cancer Centers | <b>Dana Farber</b>

Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses chemotherapy choices for patients with adjuvant breast cancer.

Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses chemotherapy choices for patients with adjuvant breast cancer.

Shulman says data have shown that other taxanes are no more efficacious and are, in fact, more toxic than paclitaxel, including nab-paclitaxel. Shulman believes that paclitaxel is the best taxane to use in this group of patients even though others may argue that docetaxel is more effective. However, Shulman says there is no good evidence to support this claim and physicians are ‘stuck' using combination chemotherapy.